Aurora Cannabis (ACB) Research & Development (2017 - 2026)

Aurora Cannabis (ACB) has reported Research & Development for 10 consecutive years, with $718996.8 the latest figure, recorded in Q1 2026.

• Quarterly Research & Development rose 31.42% year-over-year to $718996.8 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.9 million (up 9.82% YoY) and the FY2026 annual result came in at $2.9 million, up 10.06% from the prior year.
• Research & Development eased to $718996.8 in Q1 2026 per ACB's latest filing, from $934363.4 in the prior quarter.
• Over the last five years, Research & Development for ACB reached as high as $3.0 million in Q4 2022 and fell as low as $547079.4 in Q1 2025.
• A 5-year average of $1.1 million and a median of $714727.1 in 2024 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2022 — Research & Development jumped 135.15% — and 2023, when it slumped 81.05%.
• Year by year, Research & Development stood at $3.0 million in 2022, then sank by 81.05% to $574406.8 in 2023, then grew by 15.78% to $665023.9 in 2024, then soared by 40.5% to $934363.4 in 2025, then fell by 23.05% to $718996.8 in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $718996.8, $934363.4, and $656878.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.